Protirelin Peptide

(I) Differential Diagnosis of Hypothyroidism Etiology

The core clinical application of protirelin peptide lies in the precise differentiation between primary and secondary (pituitary/hypothalamic) hypothyroidism, addressing the limitations of solely measuring serum T3, T4, and TSH. Primary hypothyroidism arises from intrinsic thyroid lesions, with markedly elevated basal TSH levels. Following intravenous administration of protirelin (200–500 μg), pituitary TSH-secreting cells exhibit a robust response, with serum TSH peak values increasing 3–5 fold relative to baseline, consistent with the peak time (15–30 minutes) observed in healthy individuals.

In contrast, secondary hypothyroidism results from impaired anterior pituitary function; even with low or normal basal TSH levels, TSH shows no significant elevation (peak < 2× baseline) or a delayed response after protirelin injection. Hypothalamic hypothyroidism presents as a delayed TSH response, with peaks occurring 60–90 minutes post-injection. This method identifies the site of hypothyroid lesions, providing critical evidence for formulating clinical replacement therapy regimens, especially for patients with occult hypothyroidism who have borderline T3/T4 levels and no significant abnormalities in basal TSH.

(II) Adjunctive Diagnosis of Graves' Disease and Endocrine Exophthalmos

Graves' disease (toxic diffuse goiter) is an autoimmune hyperthyroidism characterized by excessively high circulating thyroid hormones (T3, T4), which strongly suppress the sensitivity of pituitary TSH-secreting cells to protirelin via negative feedback. In clinical testing, patients with Graves' disease and associated endocrine exophthalmos show almost no increase in serum TSH (ΔTSH < 2 mIU/L) after protirelin injection, whereas healthy individuals exhibit a 2–3 fold TSH peak relative to baseline.

This test aids in diagnosing atypical hyperthyroidism (e.g., T3-toxicosis, subclinical hyperthyroidism) and evaluates the recovery of the pituitary-thyroid axis following hyperthyroidism treatment (antithyroid drugs, radioactive iodine), determining whether sufficient thyroid hormone suppression is achieved.

(III) Assessment of Anterior Pituitary Reserve and Hypothalamic-Pituitary-Thyroid Axis Function

The protirelin test is a classical method for evaluating the reserve function of pituitary TSH secretion, suitable for endocrine screening in patients suspected of hypopituitarism, sellar tumors (e.g., pituitary adenomas), craniocerebral trauma, or post-radiotherapy. By monitoring serum TSH levels at multiple time points (0, 15, 30, 60, 90 minutes) post-injection, the responsiveness of pituitary TSH cells can be determined: a normal response indicates adequate pituitary reserve; a blunted or absent response suggests impaired pituitary secretory function; and a delayed response implies hypothalamic lesions.

Additionally, this test can be combined with gonadorelin (gonadotropin-releasing hormone) and growth hormone stimulation tests to comprehensively assess multi-hormonal secretion of the anterior pituitary and clarify the extent of pituitary lesions. Protirelin peptide also assists in verifying the adequacy of thyroid hormone replacement therapy dosage: in primary hypothyroid patients receiving levothyroxine, a normal or mildly blunted TSH response to protirelin indicates sufficient replacement dosage, while an exaggerated response suggests insufficient dosage.

(I) Neurotransmitter Modulation and Central Nervous System Regulation

Protirelin acts not only as an endocrine hormone but also as a vital central neuromodulatory peptide. Its receptors (TRH-R1, TRH-R2) are widely distributed in the cerebral cortex, hippocampus, striatum, hypothalamus, and other regions, regulating the release of multiple neurotransmitters including dopamine, acetylcholine, 5-hydroxytryptamine, and glutamate.

Studies confirm that protirelin stimulates dopamine release in the striatum and nucleus accumbens, modulating motor function and reward pathways; promotes acetylcholine release in the cortex and hippocampus, improving cognition and memory; and inhibits pathological excessive glutamate release in the hippocampus, reducing excitatory neurotoxicity. This broad neurotransmitter regulatory profile establishes protirelin as an important molecular tool in neuropsychiatric disorder research.

(II) Potential Therapeutic Exploration for Depression

Early clinical studies have identified rapid antidepressant effects of protirelin, particularly in treatment-resistant depression patients unresponsive to conventional antidepressants. Unlike traditional medications (which take 2–4 weeks to take effect), intravenous protirelin improves core depressive symptoms such as low mood, anhedonia, and sleep disturbances within hours.

Its mechanism may involve rapid rebalancing of central monoamine neurotransmitters (dopamine, 5-hydroxytryptamine) and reversing HPT axis dysfunction associated with depression (e.g., blunted TSH response in some patients). However, due to its short half-life (only minutes), requirement for intravenous administration, and transient side effects including blood pressure fluctuations and nausea in some patients, protirelin has not been approved as an antidepressant. Nevertheless, it has provided a core framework for the development of long-acting TRH analogs (e.g., taltirelin).

(III) Neuroprotection and Neurodegenerative Disease Research

Neuroprotection by protirelin has emerged as a major research focus in recent years, mediated primarily by three mechanisms:

Inhibiting excessive glutamate release to block excitotoxic neuronal apoptosis, protecting against neural injury caused by cerebral ischemia, hypoxia, and status epilepticus;

Reducing oxidative stress in brain tissue, decreasing reactive oxygen species-induced neuronal damage, and enhancing neuronal anti-apoptotic capacity;

Modulating neuroinflammation by suppressing excessive microglial activation and reducing pro-inflammatory cytokine release (e.g., TNF-α, IL-6).

Accordingly, protirelin is widely used in preclinical research on Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), spinal cord injury, and other disorders. Animal experiments demonstrate that protirelin alleviates learning and memory impairments and reduces β-amyloid deposition in Alzheimer's disease mouse models; relieves bradykinesia and protects dopaminergic neurons in Parkinson's disease models; and promotes neurological functional recovery following spinal cord injury, improving limb motor and sensory function. Furthermore, protirelin peptide serves as an adjunctive treatment for disorders of consciousness (e.g., post-traumatic coma), facilitating consciousness recovery by activating central neural pathways.

(I) Mechanistic Research on the Hypothalamic-Pituitary-Thyroid (HPT) Axis

Protirelin serves as the standard tool peptide for basic HPT axis research, extensively applied in in vitro cellular assays and animal models. In vitro, protirelin stimulation of anterior pituitary cells enables investigation of TSH and PRL synthesis and secretion regulatory mechanisms, characterization of TRH receptor signaling pathways (G protein coupling, cAMP, Ca²⁺ influx), and screening of HPT axis-modulating drugs.

In vivo, using hypothyroid, hyperthyroid, and hypophysectomized animal models, measurement of serum TSH, T3, and T4 changes post-protirelin injection clarifies HPT axis feedback regulation, functional maturation during development, and impacts of environmental factors (e.g., stress, nutrition) on the endocrine axis. Protirelin also facilitates research on TRH's cross-regulatory roles in non-thyroid endocrine axes, including the hypothalamic-pituitary-adrenal axis and growth hormone axis.

(II) Prolactin (PRL) Secretion Regulation and Related Disease Research

Protirelin specifically stimulates pituitary lactotrophs to secrete PRL, making it an essential tool for studying hyperprolactinemia and pituitary prolactinomas.

In preclinical research, the protirelin stimulation test assesses lactotroph responsiveness, distinguishing functional hyperprolactinemia from prolactinomas (characterized by markedly elevated basal PRL and blunted response to protirelin). Concurrently, protirelin is used to investigate PRL's roles in mammary development, reproductive function, and immune regulation, as well as the mechanisms of the TRH-PRL pathway in polycystic ovary syndrome, postpartum depression, and other disorders.